GLP-1 Side Effects Compared: Semaglutide vs Tirzepatide
Both semaglutide and tirzepatide most commonly cause gastrointestinal side effects — nausea, diarrhea, vomiting, constipation. Rates are broadly similar; slow dose titration is the main strategy to reduce them.
- GI effects (nausea, diarrhea, vomiting, constipation) are the most common for both drugs.
- Side effects are usually worst during dose escalation and often ease over time.
- Both carry a boxed warning for thyroid C-cell tumors based on rodent studies.
- Slow titration is the primary evidence-based strategy to reduce GI effects.
The common side effects
Both semaglutide and tirzepatide share a side-effect profile dominated by the gastrointestinal tract: nausea, diarrhea, vomiting, constipation, and abdominal discomfort. These are the effects most people experience, and they are usually most intense during dose escalation before easing as the body adjusts.
Across the STEP and SURMOUNT trials, the majority of participants reported at least one GI effect, but most were mild to moderate and relatively few discontinued because of them.
Do they differ between the drugs?
Head-to-head, the side-effect profiles are broadly similar. Both drugs work through GLP-1 receptor activation, which drives the GI effects, and tirzepatide's additional GIP activity does not appear to dramatically change the tolerability picture for most people.
Some individuals tolerate one molecule better than the other, which is not fully predictable in advance. If side effects on one are intolerable, a clinician may consider switching, but there is no universal rule that one is gentler.
| Effect | Frequency | Usually worst when |
|---|---|---|
| Nausea | Very common | Dose escalation |
| Diarrhea | Common | Dose escalation |
| Constipation | Common | Ongoing |
| Vomiting | Common | Dose escalation |
The serious warnings
Both carry a boxed warning for thyroid C-cell tumors, based on rodent studies; they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both list a risk of pancreatitis, gallbladder problems, and, rarely, more serious reactions. These are uncommon but important, and any severe abdominal pain, persistent vomiting, or signs of an allergic reaction warrant urgent medical attention.
These warnings apply to the FDA-approved products; compounded formulations carry the same molecular risks without formulation-specific safety data.
| Warning | Note |
|---|---|
| Thyroid C-cell tumors | Boxed warning; contraindicated with MTC/MEN2 history |
| Pancreatitis | Uncommon; seek care for severe abdominal pain |
| Gallbladder | Risk with rapid weight loss |
Managing side effects
The primary evidence-based strategy is slow dose titration, which is exactly why both drugs are escalated gradually rather than started at full dose. Eating smaller meals, avoiding high-fat foods, and staying hydrated are commonly advised, though the strongest evidence supports the titration schedule itself.
Persistent or worsening symptoms should be reported to the prescribing clinician rather than managed alone, and dose adjustments are a clinical decision. Do not self-adjust dosing to control side effects.
Frequently asked questions
Which has fewer side effects, semaglutide or tirzepatide?
Their profiles are broadly similar, both dominated by GI effects. Some people tolerate one better, but there is no universal rule that either is gentler.
Do side effects go away?
They are usually worst during dose escalation and often ease as the body adjusts. Slow titration is designed to reduce them.
When should I seek medical care?
For severe abdominal pain, persistent vomiting, signs of an allergic reaction, or any severe or worsening symptom, seek urgent care.
Sources
- Clinical trials via NEJM.
- STEP and SURMOUNT trial safety data.
- FDA — human drug compounding and GLP-1 status.
The numbers behind this page
Three questions to ask before acting on this entry
Every price quoted in this entry comes from the programme's own pricing page and carries the date it was captured.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
At the cheapest verified semaglutide rate of $119 a month (NexLife, 12-month plan), medication alone runs $1,428 a year, $4,284 over three and $7,140 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
What a longer horizon costs
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
At the cheapest verified semaglutide rate of $119 a month (NexLife, 12-month plan), medication alone runs $1,428 a year, $4,284 over three and $7,140 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
What is the cheapest verified GLP-1 programme?
NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.